Patent application number | Description | Published |
20090072613 | BICYCLE WHEEL SECURING STRUCTURE - A bicycle wheel securing structure includes a bicycle fork, an adapter and a holding member. The bicycle fork has two axle support portions that are spaced apart for receiving a bicycle hub therebetween. The adapter is disposed in an adapter receiving bore in one of the axle support portions. The adapter includes a threaded axle mounting opening. The holding member is operatively coupled between the adapter and the one of the axle support portions with the adapter. The holding member prevents both rotational movement of the adapter with respect to the bicycle fork and axial movement of the adapter with respect to the bicycle fork along an axis of the axle mounting opening when the holding member is in a retaining position. The adapter is rotatable within the adapter receiving bore without moving axially with respect to the bicycle fork when the holding member is in a releasing position. | 03-19-2009 |
20100025957 | BICYCLE SUSPENSION SYSTEM - A bicycle suspension system is provided with a first tubular element, a piston, a piston rod, a first sealing member and a switching valve. The piston is coupled to the piston rod, and is slidably disposed in the first tubular element. The first sealing member is disposed in the first tubular element adjacent such that a first air chamber is formed between the piston and the first sealing member. The switching valve is coupled to the first sealing member. The switching valve opens a communication passageway between the first air chamber and a second air chamber to connect the first and second air chambers when in the opened position, and closes the communication passageway between the first air chamber and the second air chamber to separate the first and second air chambers when in the closed position. | 02-04-2010 |
20110079984 | BICYCLE WHEEL SECURING STRUCTURE - A bicycle wheel securing structure includes a bicycle fork, an adapter and a holding member. The bicycle fork has two axle support portions that are spaced apart for receiving a bicycle hub therebetween. The adapter is disposed in an adapter receiving bore in one of the axle support portions. The adapter includes a threaded axle mounting opening. The holding member is operatively coupled between the adapter and the one of the axle support portions with the adapter. The holding member prevents both rotational movement of the adapter with respect to the bicycle fork and axial movement of the adapter with respect to the bicycle fork along an axis of the axle mounting opening when the holding member is in a retaining position. The adapter is rotatable within the adapter receiving bore without moving axially with respect to the bicycle fork when the holding member is in a releasing position. | 04-07-2011 |
Patent application number | Description | Published |
20090306111 | Pharmaceutical Comprising PPAR Agonist - An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye. | 12-10-2009 |
20100190833 | PHARMACEUTICAL CONTAINING PPARA AGONIST - Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. | 07-29-2010 |
20120270910 | PHARMACEUTICAL CONTAINING PPAR-DELTA AGONIST - Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoroethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. | 10-25-2012 |
Patent application number | Description | Published |
20080312093 | Method for detecting cancer and a method for suppressing cancer - An object of the invention is to find a cancer-associated gene to be used as an index for detecting canceration of cells and degree of malignancy of cancer, so as to provide a method for detecting cancer using the cancer-associated gene as an index and provide a method of suppressing/treating cancer using the cancer-associated gene as essential part. According to the present invention, specific genes which are amplified or deleted in gastric carcinoma as compared with normal cell have been collectively found, and a method for detecting cancer using amplification or deletion of these cancer-associated genes as an index is provided. Further, cancer can be suppressed by introducing a gene which is deleted in cancer cells among these cancer-associated genes into cancer and inhibiting the transcription product of the gene amplified. | 12-18-2008 |
20090011424 | Cancer-suppressing agents - It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides a cancer-suppressing agent which comprises NR1I2 gene or a homologous gene thereof; and a cancer-suppressing agent which comprises NR1I2 protein or a homologous protein thereof. | 01-08-2009 |
20090074849 | Cancer-suppressing agents - It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides a cancer-suppressing agent which comprises NR1I2 gene or a homologous gene thereof; and a cancer-suppressing agent which comprises NR1I2 protein or a homologous protein thereof. | 03-19-2009 |
20100105868 | METHOD FOR DETECTING NEUROBLASTOMA - The present invention is intended to provide a means for judging the malignancy of neuroblastoma and the progress of spontaneous regression thereof. The present invention provides a method for detecting cancer which comprises detecting activation or inactivation of the lysosomal-associated protein multispanning transmembrane 5 (LAPTM5) gene and amplification of the MYCN gene in a specimens to evaluate the malignancy of the specimens and the progress of spontaneous regression. | 04-29-2010 |
Patent application number | Description | Published |
20110275617 | OPHTHALMIC COMPOSITION - The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such as carteolol, levobunolol, betaxolol, metipranolol, timolol or propranolol. | 11-10-2011 |
20130053374 | OPHTHALMIC COMPOSITION - The present invention provides an ophthalmic composition comprising a hyperbranched polyester. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polyester increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as PEG, Polysorbate, HPMC or HEC, and beta-blockers, such as Carteolol, Levobunolol, Betaxolol, Metipranolol, Timolol or Propranolol. The concentration of the hyperbranched polyester in the ophthalmic formulation should be less than or equal to 4% (w/v) in order to avoid any cytotoxic effects on human corneal cells and thus the eye irritation. | 02-28-2013 |
20140343109 | PHARMACEUTICAL CONTAINING PPAR-delta AGONIST - Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. | 11-20-2014 |